Basic Information
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Water Solubility | 50000.0 | mg/L | >50 | mg/ml | ChemSpider |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Reference |
|---|---|---|---|---|---|---|
| AUC | 47864.3 | ng.h/ml | 47864.31 | ng.h/ml | PO, oral; fasting; | DRUGBANK |
| C Max | 1430.9 | ng/ml | 1430.93 | ng/ml | PO, oral; fasting; | DRUGBANK |
| T Max | 1.8 | h | 1.75 | h | PO, oral; fasting; | DRUGBANK | T Max | 1.0 | h | 4 | h | PO, oral; food; | DRUGBANK |
| Metabolic | 90.0 | % | 90 | % | Unchanged drug; | DRUGBANK |
| Clearance | 0.26 | L/h | 0.263 | L/h | PO, oral; | DRUGBANK | Clearance | 0.44 | L/h | 0.44 | L/h | apparent clearance; | DRUGBANK |
| Volume of Distribution | 18.5 | L | 18.5 | L | Apparent volume of distribution; at steady state; | DRUGBANK |
| Half-life | 49.0 | h | 49 | h | DRUGBANK | |
| Eliminate Route | 59.0 | % | ~59 | % | Faeces excretion; PO, oral; | DRUGBANK | Eliminate Route | 22.0 | % | ~22 | % | Urinary excretion; PO, oral; | DRUGBANK |
| Protein Binding | 99.9 | % | 99.9 | % | plasma proteins; | DRUGBANK |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for adults | 80.0 | mg/day | 80 | mg/day | Vyndaqel, Vyndamax | (tafamidis); (tafamidis meglumine) | PDR | |
| Max dose for adults | 61.0 | mg/day | 61 | mg/day | Vyndaqel, Vyndamax | (tafamidis); (tafamidis meglumine) | PDR | |
| Max dose for geriatric | 80.0 | mg/day | 80 | mg/day | Vyndaqel, Vyndamax | (tafamidis); (tafamidis meglumine) | PDR | |
| Max dose for geriatric | 61.0 | mg/day | 61 | mg/day | Vyndaqel, Vyndamax | (tafamidis); (tafamidis meglumine) | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1